Advanced High-Grade Epithelial Ovarian Cancer research hub

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

This study looks at a new drug, Mirvetuximab Soravtansine, for women with advanced ovarian, peritoneal, or fallopian tube cancer that has resisted previous treatments. It aims to see how safe and effective the drug is, especially for cancers with a specific protein.